Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion. Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development.
Subcutaneous Medications Delivery has Steadily Gained Traction Over the Last Few Years
With more than 90 approved products and over 240 clinical candidates, the field has evolved significantly as several stakeholders have sustained innovative research in the domain.
A Spate of Recent Approvals Validate the Growing Interest Amongst Stakeholders
Close to 20 subcutaneous medications have received US / EU approval since 2016, majority of them1 are required to be administered weekly / monthly through vials and prefilled syringes
The Strong Clinical Pipeline Holds Significant Promise
Nearly 60 subcutaneous drugs are currently in late stages of clinical development; monoclonal antibodies, being investigated across several therapeutic areas, are the most popular.
Several Technology Providers, with Proprietary Platforms, have Emerged as Key Enablers
Several technology developers have licensed their platforms to other pharmaceutical companies for developing subcutaneous formulation of their approved / pipeline products.
Advent of Innovative Drug Delivery Systems has Also Unfolded Many Novel Opportunities
In addition, a number of device manufacturers have emerged with their novel drug delivery systems that facilitate subcutaneous administration; we identified over 200 such systems.
As New Blockbusters Emerge, the Market will Continue to Evolve in the Long Term
The current subcutaneous biologics market is over USD 80 billion; the long term growth is likely to be driven by several antibody based products being developed for various indications.
Device Developers and Technology Providers, Amongst Others, Stand to Benefit the Most
Prefilled syringes continue to dominate the current market of subcutaneous drug delivery systems; technology developers are likely to significantly benefit from licensing agreements
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.